NAMS
The table below shows NewAmsterdam Pharma Company N.V.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Operating cash flow | -$30.60M | -$36.47M | -$54.60M | -$31.86M |
| Capital expenditure | - | - | - | - |
| Investing cash flow | -$11.51M | $2.85M | -$385.00K | -$7.00K |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $11.06M | $6.52M |
NewAmsterdam Pharma Company N.V. reported operating cash flow of -$147.78M for fiscal year 2025. That is up 6.8% from -$158.56M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$29.51M (FY 2021) to -$147.78M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $198.18M |
| $2.39M |